Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Bradley Alexander McGregor, Wanling Xie, Mehmet Asim Bilen, Matthew T Campbell, Amir Mortazavi, Jiaming Huang, Rajitha Sunkara, Praful Ravi, Amishi Yogesh Shah, Sylvan Baca, Guru P. Sonpavde, Joaquim Bellmunt, Arlene O. Siefker-Radtke, Sabina Signoretti, Eliezer Mendel Van Allen, Himisha Beltran, Rana R. McKay, Toni K. Choueiri
Institutions: Dana-Farber Cancer Institute, Emory University, The University of Texas MD Anderson Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, Beverly Hospital, Beth Israel Deaconess Medical Center, Harvard University, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, University of California San Diego
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4213073866